Written question asked by Jim Shannon (Democratic Unionist Party) on Tuesday, 16 July 2019, in the House of Commons. It was due for an answer on Thursday, 18 July 2019. It was answered by Seema Kennedy (Conservative) on Friday, 26 July 2019 on behalf of the Department of Health and Social Care.
Beta Agonists: Safety
- Question
-
To ask the Secretary of State for Health and Social Care, what steps he is taking to monitor the safety of the prescription of short-acting beta agonists.
- Answer
-
The Medicines and Healthcare products Regulatory Agency is responsible for monitoring the safety of all healthcare products in the United Kingdom, including short-acting beta agonists and oral corticosteroids to treat asthma. They receive information about safety issues from patients and clinicians through the Yellow Card Scheme. They review the product if necessary and take action to minimise risk and maximise benefit to the patients. Decisions about prescribing rest with the doctor or other prescriber who has clinical responsibility for the particular aspect of a patient’s care.
Secondary information
- Type
- Written question
- Reference
- 277732
- Session
- 2017-19
- Grouped for answer
- Yes
- Subjects
- Safety Beta agonists
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2019-07-29 13:17:39 +0100
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2017-19/277732
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2017-19/277732
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2017-19/277732